Evidence Level:Sensitive: D – Preclinical
Title:
Preclinical Activity of the MPS1 Inhibitor S81694 in Acute Lymphoblastic Leukemia (ALL)
Excerpt:S81694 induced significant apoptosis (70%) in the imatinib resistant BV173 cell line bearing the E255K-BCR-ABL1 mutation.
DOI:https://doi.org/10.1182/blood-2019-125641